Search Results - "Dalle, S."

Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study by Espi, M., Teuma, C., Novel-Catin, E., Maillet, D., Souquet, P.J., Dalle, S., Koppe, L., Fouque, D.

“…Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event (IRAE). The aim…”
Get full text

Safety of pembrolizumab for resected stage III melanoma by Pham, F, Dalle, S

“…Patients with resected stage III melanoma have a heterogeneous prognosis with an especially high risk of relapse for patients with stage IIIB, IIIC and IIID…”
Get more information

Solvent-free electrospinning of liquid polybutadienes and their in-situ photocuring by Kianfar, P., Nguyen Trieu, H.Q., Dalle Vacche, S., Tsantilis, L., Bongiovanni, R., Vitale, A.

“…A green single-step method is proposed to rapidly convert liquid polybutadienes into solid ultrafine rubber fibers by coupling electrospinning and in-situ…”
Get full text

Cutaneous adverse events: a predictor of tumour response under anti‐PD‐1 therapy for metastatic melanoma, a cohort analysis of 189 patients by Bottlaender, L., Amini‐Adle, M., Maucort‐Boulch, D., Robinson, P., Thomas, L., Dalle, S.

“…Introduction Cutaneous adverse events (AEs) are the most prevalent toxicity under checkpoint inhibitors in clinical trials. In ‘real‐life’ conditions of use,…”
Get full text

Predictors of responses to immune checkpoint blockade in advanced melanoma by Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., Weide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dréno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, J. S., Eggermont, A. M., Zitvogel, L.

“…Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune…”
Get full text

Dermoscopy of lentigo maligna melanoma: report of 125 cases by Pralong, P., Bathelier, E., Dalle, S., Poulalhon, N., Debarbieux, S., Thomas, L.

“…Summary Background  Lentigo maligna melanoma (LMM) is the most common subtype of melanoma on the face. Its presentation may be quite subtle, particularly in…”
Get full text

Component alignment and clinical outcome following total knee arthroplasty: a randomised controlled trial comparing an intramedullary alignment system with patient-specific instrumentation by Huijbregts, H J T A M, Khan, R J K, Fick, D P, Hall, M J, Punwar, S A, Sorensen, E, Reid, M J, Vedove, S Dalle, Haebich, S

“…We conducted a randomised controlled trial to assess the accuracy of positioning and alignment of the components in total knee arthroplasty (TKA), comparing…”
Get more information

Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review by Sureda, N., Phan, A., Poulalhon, N., Balme, B., Dalle, S., Thomas, L.

“…Summary Background  Subungual melanoma (SUM) is a rare entity, comprising approximately 0·7–3·5% of all melanoma subtypes. SUM histopathologically belongs to…”
Get full text

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma by Amini-Adle, M, Khanafer, N, Le-Bouar, M, Duru, G, Dalle, S, Thomas, L

“…Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the…”
Get full text

Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases by Fauconneau, A., Pham-Ledard, A., Cappellen, D., Frison, E., Prochazkova-Carlotti, M., Parrens, M., Dalle, S., Joly, P., Viraben, R., Franck, F., Ingen-Housz-Oro, S., Giacchero, D., Jullié, M.-L., Vergier, B., Merlio, J.-P., Beylot-Barry, M.

“…Summary Background Transformed mycosis fungoides (TMF) large cells may express CD30 antigen, and because of this, the differential diagnosis between CD30‐rich…”
Get full text

Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients by Julia, F., Petrella, T., Beylot-Barry, M., Bagot, M., Lipsker, D., Machet, L., Joly, P., Dereure, O., Wetterwald, M., d'Incan, M., Grange, F., Cornillon, J., Tertian, G., Maubec, E., Saiag, P., Barete, S., Templier, I., Aubin, F., Dalle, S.

“…Summary Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by malignant proliferation of a contingent blastic…”
Get full text

Mycosis fungoides in patients with multiple sclerosis: A report of two cases by Donzel, M., Balme, B., Dalle, S.

Get full text

Quercetin induces insulin secretion by direct activation of L‐type calcium channels in pancreatic beta cells by Bardy, G, Virsolvy, A, Quignard, J F, Ravier, M A, Bertrand, G, Dalle, S, Cros, G, Magous, R, Richard, S, Oiry, C

“…Background and Purpose Quercetin is a natural polyphenolic flavonoid that displays anti‐diabetic properties in vivo. Its mechanism of action on…”
Get full text

Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient by Eckert, A, Schoeffler, A, Dalle, S, Phan, A, Kiakouama, L, Thomas, L

Get more information

Dermoscopy, a useful tool for general practitioners in melanoma screening: a nationwide survey by Chappuis, P., Duru, G., Marchal, O., Girier, P., Dalle, S., Thomas, L.

“…Summary Background Dermoscopy improves diagnostic accuracy in melanoma, as shown by several meta‐analyses. Although it is used by general practitioners (GPs)…”
Get full text

Cutaneous apocrine adenocarcinoma in a PALB2 germline pathogenic variant carrier by Idoudi, S., Golmard, L., Harou, O., Martin‐Denavit, T., Tantot, J., Dalle, S.

Get full text

Image Gallery: Unilateral eyebrow depigmentation by Amini Adle, M., Chastagner, M., Mansard, S., Dalle, S.

Get full text

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases by Mabrut, E., Mainbourg, S., Peron, J., Maillet, D., Dalle, S., Fontaine Delaruelle, C., Grolleau, E., Clezardin, P., Bonnelye, E., Confavreux, C.B., Massy, E.

“…•Bone metastasis significantly affects patient survival and quality of life in advanced solid tumors, and denosumab is used to prevent skeletal-related events…”
Get full text

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort by Kandel, M., Allayous, C., Dalle, S., Mortier, L., Dalac, S., Dutriaux, C., Leccia, M.T., Guillot, B., Saiag, P., Lacour, J.P., Legoupil, D., Lesimple, T., Aubin, F., Beylot-Barry, M., Brunet-Possenti, F., Arnault, J.P., Granel-Brocard, F., Stoebner, P.E., Dupuy, A., Maubec, E., Grob, J.J., Dreno, B., Rotolo, F., Ballon, A., Michiels, S., Lebbe, C., Borget, I.

“…Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which…”
Get full text

Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data by Di Filippo, Y., Dalle, S., Mortier, L., Dereure, O., Dalac, S., Dutriaux, C., Leccia, M.-T., Legoupil, D., Saiag, P., Brunet-Possenti, F., Arnnault, J.-P., Maubec, E., Granel-Brocard, F., De Quatrebarbes, J., Aubin, F., Lesimple, T., Beylot-Barry, M., Stoebner, P.-E., Dupuy, A., Stephan, A., Grob, J.-J., Lefevre, W., Oriano, B., Allayous, C., Lebbé, C., Montaudié, H.

“…The ‘obesity paradox’ suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those…”
Get full text